BACKGROUND: Previous research has already shown @entity1252 ( @entity1252 ) to have severe consequences on pregnancy outcomes. However, insufficient number of @entity1 , which were mainly limited to one particular region, limited outcomes analyzed and lack of evidence based analysis to support systematic reviews of the literature were the limitations observed. Therefore, by improving these limitations, we aimed to systematically show the impact of @entity1252 on maternal and fetal outcomes following pregnancy. METHODS: The Cochrane Database of Randomized Controlled Trials, EMBASE and Medline databases were carefully searched for appropriately relevant English language studies comparing maternal and/or fetal outcomes (endpoints) in pregnant @entity1 with and without @entity1252 . With the presence of discontinuous data, risk ratios (RR) and 95% confidence intervals (CI) were calculated and the final analysis was carried out by RevMan 5.3 software. RESULTS: Eleven studies with a total number of 529,778 @entity1 were included. This current analysis showed cesarean operation to be significantly higher in @entity1 with @entity1252 (RR: 1.85, 95% CI: 1.63-2.10; P  =  0.00001). @entity1468 and @entity101 also significantly affected @entity1 with @entity1252 , (RR: 1.91, 95% CI: 1.44-2.53; P  =  0.00001) and (RR: 1.99, 95% CI: 1.54-2.56; P  =  0.00001) respectively. In addition, @entity2208 , @entity1031 , and post-partum @entity281 were also significantly higher in the @entity1252 subgroup (RR: 1.51, 95% CI: 1.26-1.82; P  =  0.0001), (RR: 11.29, 95% CI: 6.05-21.07; P  =  0.00001) and (RR: 4.35, 95% CI: 2.69-7.03; P  =  0.00001) respectively. Live birth significantly favored @entity1 who were born from mothers without @entity1252 (RR: 1.38, 95% CI: 1.14-1.67; P  =  0.001). Significantly higher premature birth and @entity1 classified as 'small for gestational age' were associated with @entity1252 , (RR: 3.05, 95% CI: 2.56-3.63; P  =  0.00001) and (RR: 1.69, 95% CI: 1.53-1.88; P  =  0.00001) respectively. In addition, @entity1252 was significantly associated with increased number of @entity1 that required neonatal intensive care unit and @entity1 with @entity154 (RR: 2.76, 95% CI: 2.27-3.35; P  =  0.00001) and (RR: 2.63, 95% CI: 1.93-3.58; P  =  0.00001) respectively. CONCLUSIONS: This meta-analysis has shown @entity1252 to indeed have a high impact on maternal and fetal outcomes following pregnancy. Therefore, special treatments and care should be allocated to those @entity1 in order to manage adverse outcomes that might follow, and to improve successful normal delivery, term @entity1 and to reduce @entity154 in @entity1 who were born from mothers with @entity1252 .

Impact of XXXX on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016.

@entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients', 'infants'] @entity2208 :: ('MESH:D000022', 'Disease') :: ['spontaneous abortion'] @entity154 :: ('MESH:D000013', 'Disease') :: ['congenital abnormalities', 'congenital defects'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1468 :: ('MESH:D011225', 'Disease') :: ['Pre-eclampsia'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic disease']
@entity1252 :: (MESH:D008180,Disease) :: ['systemic lupus erythematosus']
